[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623033":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":62,"collaborators":25,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":25,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":25,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":25,"overallStatus":84,"whyStopped":25,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"University of Medicine, Mandalay","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Alternate-day group","EXPERIMENTAL","Alternate-day group receiving oral iron III polymaltose complex 3mg\u002Fkg\u002Fday",[13,14],"Drug: Alternate-day oral Iron (III)-hydroxide polymaltose complex","Drug: Iron (III)-hydroxide polymaltose complex - daily oral dosing Iron (III)-hydroxide polymaltose complex - alternate-day oral dosing",{"label":16,"type":10,"description":17,"interventionNames":18},"Daily group","Daily group receiving oral iron III polymaltose complex 3mg\u002Fkg\u002Fday",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Alternate-day oral Iron (III)-hydroxide polymaltose complex","The intervention uses the same oral Iron (III)-hydroxide polymaltose complex in both study arms, differing only in dosing frequency (alternate-day versus daily administration)",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Iron (III)-hydroxide polymaltose complex - daily oral dosing Iron (III)-hydroxide polymaltose complex - alternate-day oral dosing","This intervention uses oral Iron (III)-hydroxide polymaltose complex, a non-ionic ferric iron preparation, administered as a liquid formulation with dosing based on body weight. This study evaluates the same iron preparation in both study arms, with the dosing frequency (daily versus alternate-day administration) as the only variable. This approach allows assessment of the impact of dosing schedule on haemoglobin response, gastrointestinal tolerability, and treatment adherence in children with iron deficiency anaemia, while minimizing confounding from formulation-related differences.",[9,16],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Zayar Kyaw Win, MBBS, MMed Sc (Paediatrics)","CONTACT","+9595123141","dr.zayar.k.w@gmail.com",[37,56],{"facility":38,"status":25,"city":39,"state":40,"zip":25,"country":41,"countryCode":25,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Paediatrics ward, 300 Beeded Teaching Hospital, Mandalay","Mandalay","Mandalay Region","Burma",{"type":43,"coordinates":44},"Point",[45,46],96.08359,21.97473,{"lat":46,"lon":45},[49,53],{"name":50,"role":33,"phone":51,"phoneExt":25,"email":52},"Kyaw Myo, Professor of Paediatrics","+959798599253","kyawmyo@ummedu.com",{"name":54,"role":55,"phone":25,"phoneExt":25,"email":25},"Zayar Kyaw Win, MBBS, MMedSc (Paediatrics)","PRINCIPAL_INVESTIGATOR",{"facility":38,"status":25,"city":39,"state":40,"zip":25,"country":41,"countryCode":25,"cosmosGeoPoint":57,"geoPoint":59,"contacts":60},{"type":43,"coordinates":58},[45,46],{"lat":46,"lon":45},[61],{"name":50,"role":33,"phone":51,"phoneExt":25,"email":52},{"type":55,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Dr Zayar Kyaw Win","Senior Consultant Paediatrician, Department of Paediatrics","100623033","phase-4-alternate-day-versus-daily-oral-iron-therapy-in-children-with-iron-deficiency-anaemia-100623033",false,"NCT07391371","Alternate-day Versus Daily Oral Iron Therapy in Children With Iron Deficiency Anaemia","Inclusion criteria Six months to 12 years old children with iron deficiency anaemia\n\nExclusion criteria\n\n1. Critically ill child\n2. Children with documented chronic illnesses (e.g., known renal failure, known liver disease)\n3. Children with known cases of thalassemia\n4. Children with severe anaemia requiring transfusion\n5. Children who received blood transfusion within the preceding 3 months",true,"ALL","6 Months","12 Years",{"count":76,"type":77},60,"ESTIMATED","INTERVENTIONAL",[80],"PHASE4","The goal of this clinical trial is to find out whether Iron (III)-hydroxide polymaltose complex (IPC) given on an alternate-day schedule works as well as daily dosing in treating iron deficiency anaemia in children. The study will also look at the safety and tolerability of IPC.\n\nThe main questions this study aims to answer are:\n\nDoes alternate-day oral IPC improve haemoglobin levels and serum ferritin level as effectively as daily oral IPC?\n\nDoes alternate-day dosing reduce gastrointestinal side effects compared to daily dosing?\n\nDoes alternate-day dosing improve treatment adherence in children?\n\nResearchers will compare alternate-day IPC with daily IPC to determine the most effective and well-tolerated dosing schedule for children with iron deficiency anaemia.\n\nParticipants will:\n\nReceive oral Iron (III)-hydroxide polymaltose complex either daily or on alternate days for 12 weeks treatment period\n\nAttend regular clinic visits for clinical assessment and blood investigations\n\nBe monitored for adverse effects, adherence to treatment, and improvement in haemoglobin and serum ferritin levels",[83],"Iron Deficiency Anemia","NOT_YET_RECRUITING","2026-01-29",{"date":87,"type":88},"2026-02-05","ACTUAL",{"date":90,"type":77},"2026-02-01",{"date":92,"type":77},"2027-01-31",{"name":5,"class":6},2]